Douglas S. Ingram - 07 Dec 2025 Form 4 Insider Report for Sarepta Therapeutics, Inc. (SRPT)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: SRPT
Reported as of: 07 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Dec 2025, 20:30:03 UTC
Prior SEC filing: 06 Jun 2025
Next SEC filing: 18 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Cristin L. Rothfuss, as Attorney-in-Fact for Douglas S. Ingram

Key filing fact

Douglas S. Ingram filed Form 4 for Sarepta Therapeutics, Inc. (SRPT) on 09 Dec 2025.

Key facts

This page summarizes Douglas S. Ingram's Form 4 filing for Sarepta Therapeutics, Inc. (SRPT).
5 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 09 Dec 2025, 20:30.

Change

Previous filing in this sequence was filed on 06 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001190644 Primary reporting owner

INGRAM DOUGLAS S

Relationship: Chief Executive Officer, Director
Address: 215 FIRST STREET, SUITE 415, CAMBRIDGE
Signature: /s/ Cristin L. Rothfuss, as Attorney-in-Fact for Douglas S. Ingram
Signature date: 09 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SRPT transaction

Common Stock

Award

Transaction value: $0
Shares: +50,000
Change %: +13%
Price: $0.000000
Shares after: 440,307
Date: 07 Dec 2025
Ownership: Direct
Footnotes: F1

SRPT transaction

Common Stock

Award

Transaction value: $0
Shares: +50,000
Change %: +11%
Price: $0.000000
Shares after: 490,307
Date: 07 Dec 2025
Ownership: Direct
Footnotes: F2

SRPT transaction

Common Stock

Award

Transaction value: $0
Shares: +73,001
Change %: +15%
Price: $0.000000
Shares after: 563,308
Date: 07 Dec 2025
Ownership: Direct
Footnotes: F3

SRPT transaction

Common Stock

Award

Transaction value: $0
Shares: +96,541
Change %: +17%
Price: $0.000000
Shares after: 659,849
Date: 07 Dec 2025
Ownership: Direct
Footnotes: F4

SRPT transaction

Common Stock

Award

Transaction value: $0
Shares: +269,542
Change %: +41%
Price: $0.000000
Shares after: 929,391
Date: 07 Dec 2025
Ownership: Direct
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The Reporting Person was granted performance-contingent restricted stock units ("Performance-Contingent RSUs"), as described in the Company's 2018 Equity Incentive Plan. Each Performance-Contingent RSU represents the right to receive one share of common stock. The Performance-Contingent RSUs are subject to service- and performance-based vesting criteria.

Footnote F2

The Reporting Person was granted restricted shares, as described in the Company's 2018 Equity Incentive Plan. The restricted shares are subject to service- and performance-based vesting criteria.

Footnote F3

The Reporting Person was granted Performance Units, as described in the Company's 2018 Equity Incentive Plan. The Performance Units are subject to service- and performance-based vesting criteria.

Footnote F4

The Reporting Person was granted Performance Shares, as described in the Company's 2018 Equity Incentive Plan. The Performance Shares are subject to service- and performance-based vesting criteria.

Footnote F5

The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs are subject to service- and performance-based vesting criteria.